spacer
home > ict > autumn 2017 > three-fold solution
PUBLICATIONS
International Clinical Trials

Three-Fold Solution

Astonishingly, the same four problems that delayed trial
start-ups 20 years ago are still doing so today; very little has
changed. Sponsors, CROs and investigator sites consistently
name redundant training and certification, budgeting
and contracting issues, vendor relations and scheduling
concerns as the top reasons that site activation can take
up to a year (1).

Certainly, these are not the only issues that cause stoppage.
Feasibility studies, regulatory matters and institutional
review board (IRB) approvals play their part, but the ‘big
four’ remain the same. However, stakeholders can embrace
a three-fold solution to speed up trial start dates, which
has the potential to slash site activation times to as little
as 30 days.

The ‘Big Four’

Before turning to the solution, having a clear
understanding of the problems preventing swift site
activation is important.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sean Stanton is Senior Vice President Global Operations at Bioclinica Research Network. He has dedicated the last 25 years of his career to creating successful, high-performing research sites and, to date, has led the start-up of 25 trial sites, six inpatient hospitals and 19 outpatient clinics. More than 5,000 trials have been conducted at these sites, leading to over 50 drug approvals, and, in these, he directed recruitment for the screening of 2,000 to 6,000 patients annually. A sought-after industry expert, Sean has brought innovative thinking to research in all aspects of site practice, from purchasing and resourcing to the use of benchmarking and metrics in business planning to guide trial growth.
spacer
Sean Stanton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Releases Environmental, Social and Governance Report

ICON announced today the release of its 2020 Environmental, Social and Governance (ESG) Report.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement